Global Cancer Statistics 2022 reported the prevalence and high mortality rate of lung
cancer. Notably, non-small cell lung cancer (NSCLC) accounts for the majority of the …

Lung cancer, with non-small cell lung cancer (NSCLC) being the major type, is the second
most common malignancy and the leading cause of cancer-related death globally …

A banner year for immunotherapy and targeted therapy | Nature Reviews Clinical Oncology
Skip to main content Thank you for visiting nature.com. You are using a browser version with …

Introduction Immunotherapy (IO) has established a new milestone in lung cancer treatment.
Several registrational studies have approved immune checkpoint inhibitors (ICIs) in different …

Simple Summary Immunotherapy stands as a cornerstone in the treatment of advanced lung
cancer patients without an oncogenic driver mutation. This comprehensive review provides …

Lung cancer is the most common cause of cancer-related deaths worldwide. Non-small-cell
lung cancer (NSCLC) represents the majority of lung cancer cases, and its standard …

Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of
patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective …

Platinum-based chemotherapy has long been the mainstay first-line therapy for patients with
non-small-cell lung cancer without a targetable driver mutation, but has limited effectiveness …

Non-small cell lung cancer (NSCLC) is still the leading cause of cancer death worldwide,
with a poor prognosis. In the era of immunotherapies, the field is rapidly changing, and the …

Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of
patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective …